Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1998 Sep 8;159(5):469–476.

The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring

T W Wilson 1, Y Lacourcière 1, C C Barnes 1
PMCID: PMC1229641  PMID: 9757170

Abstract

BACKGROUND: Losartan potassium is a recently marketed angiotensin II receptor antagonist. Previous studies have suggested that its full antihypertensive efficacy may be delayed for up to 12 weeks. The authors compared the antihypertensive efficacy and tolerability of losartan at 6 and 12 weeks with those of amlodipine besylate, a commonly used calcium antagonist. METHODS: This multicentre, randomized, double-blind clinical trial studied 302 patients with mild or moderate hypertension in 1995. Of the 302, 97 also underwent ambulatory blood pressure monitoring (ABPM). After a 4-week placebo run-in period, the patients were randomly assigned to group A, B or C for 12 weeks. Those in groups A and B began treatment with losartan at 50mg/d, and those in group C began with amlodipine at 5 mg/d. If the blood pressure remained uncontrolled after 6 weeks, subjects in group A had their losartan dose doubled (to 100 mg/d), those in group B were given hydrochlorothiazide (12.5 mg/d) in addition to the losartan, which remained at 50 mg/d, and patients in group C had their amlodipine dose doubled (to 10 mg/d). RESULTS: At 12 weeks all 3 regimens reduced office-recorded diastolic blood pressure (DBP) with the patient sitting. The mean reduction in group A was 8.7 mm Hg (95% confidence interval [CI] 7.3 to 10.1) (p < 0.001), in group B 12.5 mm Hg (95% CI 11.0 to 14.0) (p < 0.001) and in group C 12.9 mm Hg (95% CI 11.4 to 14.5) (p < 0.001). Losartan alone lowered sitting DBP to a lesser degree than the other 2 treatments (p < 0.01). In contrast, ABPM readings, whether 24-hour, daytime or nighttime, were not different among the regimens. Comparison of the results at 6 weeks yielded similar findings. Adverse effects were uncommon and were not different among the groups, with the exception of ankle edema, which was more frequent in group C. INTERPRETATION: Losartan alone reduces both office and ABPM readings. The observed changes in office-recorded sitting DBP suggest that losartan is less effective than amlodipine or the combination of losartan and hydrochlorothiazide, but ABPM did not confirm this difference. Perhaps changes in office readings measure different attributes of a drug than does ABPM.

Full Text

The Full Text of this article is available as a PDF (143.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abernethy D. R. An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. Am J Cardiol. 1994 Jan 27;73(3):10A–17A. doi: 10.1016/0002-9149(94)90269-0. [DOI] [PubMed] [Google Scholar]
  2. Baba T., Neugebauer S. The link between insulin resistance and hypertension. Effects of antihypertensive and antihyperlipidaemic drugs on insulin sensitivity. Drugs. 1994 Mar;47(3):383–404. doi: 10.2165/00003495-199447030-00002. [DOI] [PubMed] [Google Scholar]
  3. Chan J. C., Critchley J. A., Lappe J. T., Raskin S. J., Snavely D., Goldberg A. I., Sweet C. S. Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens. 1995 Sep;9(9):765–771. [PubMed] [Google Scholar]
  4. Cheung D. G., Gasster J. L., Weber M. A. Assessing duration of antihypertensive effects with whole-day blood pressure monitoring. Arch Intern Med. 1989 Sep;149(9):2021–2025. [PubMed] [Google Scholar]
  5. Collins R., MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull. 1994 Apr;50(2):272–298. doi: 10.1093/oxfordjournals.bmb.a072892. [DOI] [PubMed] [Google Scholar]
  6. Dimenäs E., Wallander M. A., Svärdsudd K., Wiklund I. Aspects of quality of life on treatment with felodipine. Eur J Clin Pharmacol. 1991;40(2):141–147. doi: 10.1007/BF00280068. [DOI] [PubMed] [Google Scholar]
  7. Furberg C. D., Psaty B. M., Meyer J. V. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995 Sep 1;92(5):1326–1331. doi: 10.1161/01.cir.92.5.1326. [DOI] [PubMed] [Google Scholar]
  8. Haynes R. B., Lacourcière Y., Rabkin S. W., Leenen F. H., Logan A. G., Wright N., Evans C. E. Report of the Canadian Hypertension Society Consensus Conference: 2. Diagnosis of hypertension in adults. CMAJ. 1993 Aug 15;149(4):409–418. [PMC free article] [PubMed] [Google Scholar]
  9. Jachuck S. J., Brierley H., Jachuck S., Willcox P. M. The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract. 1982 Feb;32(235):103–105. [PMC free article] [PubMed] [Google Scholar]
  10. Kostis J. B., Rosen R. C., Brondolo E., Taska L., Smith D. E., Wilson A. C. Superiority of nonpharmacologic therapy compared to propranolol and placebo in men with mild hypertension: a randomized, prospective trial. Am Heart J. 1992 Feb;123(2):466–474. doi: 10.1016/0002-8703(92)90662-f. [DOI] [PubMed] [Google Scholar]
  11. Lacourcière Y., Leenen F., Rangno R., Spence J. D., Lenis J. H., Myers M. G. Discrepancies between clinic and ambulatory blood pressure responses to cilazapril therapy. Can J Cardiol. 1994 Jul-Aug;10(6):605–610. [PubMed] [Google Scholar]
  12. Lind L., Pollare T., Berne C., Lithell H. Long-term metabolic effects of antihypertensive drugs. Am Heart J. 1994 Dec;128(6 Pt 1):1177–1183. doi: 10.1016/0002-8703(94)90749-8. [DOI] [PubMed] [Google Scholar]
  13. Lo M. W., Goldberg M. R., McCrea J. B., Lu H., Furtek C. I., Bjornsson T. D. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther. 1995 Dec;58(6):641–649. doi: 10.1016/0009-9236(95)90020-9. [DOI] [PubMed] [Google Scholar]
  14. MacKay J. H., Arcuri K. E., Goldberg A. I., Snapinn S. M., Sweet C. S. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med. 1996 Feb 12;156(3):278–285. [PubMed] [Google Scholar]
  15. Neaton J. D., Grimm R. H., Jr, Prineas R. J., Stamler J., Grandits G. A., Elmer P. J., Cutler J. A., Flack J. M., Schoenberger J. A., McDonald R. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA. 1993 Aug 11;270(6):713–724. [PubMed] [Google Scholar]
  16. O'Brien E., O'Malley K., Cox J., Stanton A. Ambulatory blood pressure monitoring in the evaluation of drug efficacy. Am Heart J. 1991 Mar;121(3 Pt 2):999–1006. doi: 10.1016/0002-8703(91)90611-k. [DOI] [PubMed] [Google Scholar]
  17. Oparil S., Barr E., Elkins M., Liss C., Vrecenak A., Edelman J. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther. 1996 Jul-Aug;18(4):608–625. doi: 10.1016/s0149-2918(96)80212-8. [DOI] [PubMed] [Google Scholar]
  18. Packer M., O'Connor C. M., Ghali J. K., Pressler M. L., Carson P. E., Belkin R. N., Miller A. B., Neuberg G. W., Frid D., Wertheimer J. H. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996 Oct 10;335(15):1107–1114. doi: 10.1056/NEJM199610103351504. [DOI] [PubMed] [Google Scholar]
  19. Pitt B., Segal R., Martinez F. A., Meurers G., Cowley A. J., Thomas I., Deedwania P. C., Ney D. E., Snavely D. B., Chang P. I. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet. 1997 Mar 15;349(9054):747–752. doi: 10.1016/s0140-6736(97)01187-2. [DOI] [PubMed] [Google Scholar]
  20. Stason W. B. Economics in hypertension management: cost and quality trade-offs. J Hypertens Suppl. 1987 Feb;5(1):S55–S59. [PubMed] [Google Scholar]
  21. Waeber B., Rutschmann B., Nüssberger J., Brunner H. R. Evaluation of antihypertensive therapy: discrepancies between office and ambulatory recorded blood pressure. J Hypertens Suppl. 1991 Dec;9(3):S53–S56. [PubMed] [Google Scholar]
  22. Whelton P. K., Perneger T. V., Brancati F. L., Klag M. J. Epidemiology and prevention of blood pressure-related renal disease. J Hypertens Suppl. 1992 Dec;10(7):S77–S84. [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES